Sorrento Therapeutics Stock Price and Value Analysis

Should you buy Sorrento Therapeutics stock? (NasdaqCM:SRNE). Let's see how it does in our automated value investing analysis system.

  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.
  • This company pays no dividend.

Inside the SRNE Numbers

SRNE Price
(Sorrento Therapeutics stock price per share)
[?] PE Ratio versus Sector 89% higher than other Healthcare stocks
[?] PE Ratio versus Industry 33% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 56%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 60,672,348 shares shorted. With 437,685,863 shares available for purchase and an average trading volume over the past 10 trading days of 8,051,370, it would take at least 7.536 days for all of the short holders to cover their shorts.

Is Sorrento Therapeutics Stock on Sale?

Based on our analysis, we believe that you should not buy Sorrento Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy SRNE Stock?

Does Sorrento Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.